Korean Pharma Earnings Roundup: Dong-A, Green Cross Retain Leading Positions While Yuhan, LG Life, Hanmi Struggle
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Of South Korea's five top pharmaceutical companies, Dong-A and Green Cross did relatively well in 2010, retaining their leading positions while Yuhan, LG Life Sciences and Hanmi failed to witness upward momentum amid a tightened government grip on the local pharmaceutical industry
You may also be interested in...
Korea's Yuhan Signs Deal To Sell Gilead's Viread In Korea
SEOUL - South Korea's Yuhan Corp. said it signed an agreement March 30 with Gilead Sciences Inc. to sell the latter's hepatitis B drug Viread (tenofovir) in Korea, beginning in the second half of this year after winning approval from Korea FDA
Korea's Yuhan Signs Deal To Sell Gilead's Viread In Korea
SEOUL - South Korea's Yuhan Corp. said it signed an agreement March 30 with Gilead Sciences Inc. to sell the latter's hepatitis B drug Viread (tenofovir) in Korea, beginning in the second half of this year after winning approval from Korea FDA
Biosimilars Aid Korea's Celltrion To Post Record Sales And Profit In FY 2010
SEOUL - South Korea's biosimilar front-runner Celltrion reported an all-time record high performance for sales and net profit in 2010, mainly from sales of its biosimilars of Roche's breast cancer agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis drug Remicade (infliximab) to countries in South America, the Middle East and Asia